Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Sep 25:2020:7610678.
doi: 10.1155/2020/7610678. eCollection 2020.

Comparison of Primer-Probe Sets among Different Master Mixes for Laboratory Screening of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Affiliations
Comparative Study

Comparison of Primer-Probe Sets among Different Master Mixes for Laboratory Screening of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hoang Quoc Cuong et al. Biomed Res Int. .

Abstract

Background: There is a shortage of chemical reagents for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnosis and a surge of SARS-CoV-2 cases, especially in limited-resource settings. Therefore, the combination of an optimal assay kit is necessary.

Methods: We compared the ability to screen SARS-CoV-2 among three primer-probe sets in two different master mixes, Invitrogen™ SuperScript™ III One-Step RT-PCR and LightCycler Multiplex RNA Virus Master.

Results: The assay with TIB-Molbiol, IDT, and Phu Sa sets for LightCycler Multiplex RNA Virus Master or Invitrogen™ SuperScript™ III One-Step RT-PCR showed positive results from a single reaction of triplicate in the three days of 4.8 copies per reaction. R squared and amplification efficiency were 0.97 and ranged from 107 to 108%, respectively.

Conclusions: Our findings indicated that TIB-Molbiol, IDT, and Phu Sa primer-probe sets could be beneficial for the laboratory screening of SARS-CoV-2 by RT-qPCR assay of E gene. There is a need to consider the combination of these reagent sets as a new strategy to increase the testing capacity of screening programs for COVID-19.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest.

Similar articles

Cited by

References

    1. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 97. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2....
    1. Hellewell J., Abbott S., Gimma A., et al. Feasibility of Controlling COVID-19 Outbreaks by Isolation of Cases and Contacts. The Lancet Global Health. 2020;8(4):e488–e496. doi: 10.1016/S2214-109X(20)30074-7. - DOI - PMC - PubMed
    1. Zheng C., Wang J., Guo H., et al. Risk-adapted treatment strategy for COVID-19 patients. International Journal of Infectious Diseases. 2020;94:74–77. doi: 10.1016/j.ijid.2020.03.047. - DOI - PMC - PubMed
    1. Toms D., Li J., Cai H. Y. Evaluation of WHO listed COVID-19 qPCR primers and probe in silico with 375 SERS-CoV-2 full genome sequences. medRxiv; 2020. - DOI
    1. Nalla A. K., Casto A. M., Huang M. L. W., et al. Comparative performance of SARS-CoV-2 detection assays using seven different primer/probe sets and one assay kit. Journal of Clinical Microbiology. 2020;58(6) doi: 10.1128/JCM.00557-20. - DOI - PMC - PubMed

Publication types

MeSH terms